
Ultra-Trace NMBA Detection Using HILIC-MS
Learn how Resolian achieved 0.8 ng/mL NMBA detection using HILIC-MS – overcoming reverse-phase limitations for ultra-trace nitrosamine analysis in drug products.

Learn how Resolian achieved 0.8 ng/mL NMBA detection using HILIC-MS – overcoming reverse-phase limitations for ultra-trace nitrosamine analysis in drug products.
Discover how Resolian’s platform SFC-UV method analyzes vitamin E across multiple formulations – reducing organic solvent use while meeting GMP requirements.
Discover how Resolian increased LC-MS sensitivity by 438% using Design of Experiments – achieving required detection limits without new equipment investment.
False positives in nitrosamine testing can trigger unnecessary product recalls, regulatory scrutiny, and supply chain disruptions—threatening patient access to critical therapies. But what if the contamination isn’t from your product at all?
🔬 How do you measure complex modality molecules at the lowest possible concentrations?
For modern therapies like antibody-drug conjugates (ADCs) and inhzlation drugs, precise bioanalysis at picogram levels is essential to ensure both efficacy and safety. At Resolian, we specialize in ultrasensitive assays that push the boundaries of detection.

Precision, efficiency, and scientific expertise are essential in today’s fast-moving bioanalytical landscape. At Resolian, we’ve taken a bold step forward—restructuring teams, refining method development processes, and strategically implementing automation to enhance service delivery.
Min Meng, Chief Operations Officer at Resolian. The interview focuses on the bioanalysis of oligonucleotide therapeutics, a rapidly evolving area in drug development. Min Meng, with 20+ years of experience in this field, provides valuable insights into the unique challenges and advantages of these therapies.

In this visual podcast we explore why Australia is an attractive destination for early-phase clinical trials, highlighting the benefits of speed, quality, and cost-effectiveness.
The expert panel discussion delves into Australia’s unique regulatory pathways, the R&D tax incentives, operational logistics, and how early-phase data supports global drug development.

In a globalized life sciences industry, maintaining consistent quality standards across multiple international sites is a major challenge.

Explore the history that shaped Resolian and get a sneak peek into our future plans with our new video series…
Chief Scientific Officer
Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade.
Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia.
Chief Executive Officer
Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD.
Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.